151
|
Bisson WH, Zhang Z, Welsh K, Huang JW, Ryan J, Reed JC, Pellecchia M. Binding properties of the C-terminal domain of VIAF. Chem Biol Drug Des 2009; 72:331-6. [PMID: 19012568 DOI: 10.1111/j.1747-0285.2008.00719.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The protein X-linked inhibitor of apoptosis (XIAP) plays an important role in caspase inactivation and as a consequence in the inhibition of apoptosis. It is known that IAP antagonists are able to specifically bind XIAP and reactivate caspase activity stimulating apoptosis. The viral IAP-associated factor (VIAF) protein is a novel IAP-interacting factor able to modulate caspase activation during apoptosis. We show that the C-terminal domain of VIAF (c-VIAF) is not able in vitro to behave as a direct IAP antagonist. By [15N-1H] HSQC NMR studies we revealed that c-VIAF binds to the RING domain of XIAP and characterized the important residues involved in the binding. Through 1D 1H-NMR screening of 1000 compounds from an in-house collection, we found that compound BI-86-E10 is able to bind to c-VIAF in a region adjacent to that interacting with the RING domain of XIAP, as supported by homology modeling and computational docking studies. After an initial round of SAR, the compound analog BI-86-E6 was found to bind with a K(d) value of 16.5 microM. These initial compounds may serve as chemical probes for further functional studies, possibly aimed at validating c-VIAF as a novel target for antiviral drug development.
Collapse
Affiliation(s)
- William H Bisson
- The Burnham Institute for Medical Research, 10901 North Torrey Pines Rd, La Jolla, CA 92037, USA
| | | | | | | | | | | | | |
Collapse
|
152
|
Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, Miller RS, Yi H, Shangary S, Sun Y, Meagher JL, Stuckey JA, Wang S. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68:9384-93. [PMID: 19010913 DOI: 10.1158/0008-5472.can-08-2655] [Citation(s) in RCA: 154] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Small-molecule Smac mimetics are being developed as a novel class of anticancer drugs. Recent studies have shown that Smac mimetics target cellular inhibitor of apoptosis protein (cIAP)-1/2 for degradation and induce tumor necrosis factor-alpha (TNFalpha)-dependent apoptosis in tumor cells. In this study, we have investigated the mechanism of action and therapeutic potential of two different types of novel Smac mimetics, monovalent SM-122 and bivalent SM-164. Our data showed that removal of cIAP-1/2 by Smac mimetics or small interfering RNA is not sufficient for robust TNFalpha-dependent apoptosis induction, and X-linked inhibitor of apoptosis protein (XIAP) plays a critical role in inhibiting apoptosis induction. Although SM-164 is modestly more effective than SM-122 in induction of cIAP-1/2 degradation, SM-164 is 1,000 times more potent than SM-122 as an inducer of apoptosis in tumor cells, which is attributed to its much higher potency in binding to and antagonizing XIAP. SM-164 induces rapid cIAP-1 degradation and strong apoptosis in the MDA-MB-231 xenograft tumor tissues and achieves tumor regression, but has no toxicity in normal mouse tissues. Our study provides further insights into the mechanism of action for Smac mimetics and regulation of apoptosis by inhibitor of apoptosis proteins. Furthermore, our data provide evidence that SM-164 is a promising new anticancer drug for further evaluation and development.
Collapse
Affiliation(s)
- Jianfeng Lu
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
153
|
Mastrangelo E, Cossu F, Milani M, Sorrentino G, Lecis D, Delia D, Manzoni L, Drago C, Seneci P, Scolastico C, Rizzo V, Bolognesi M. Targeting the X-Linked Inhibitor of Apoptosis Protein through 4-Substituted Azabicyclo[5.3.0]alkane Smac Mimetics. Structure, Activity, and Recognition Principles. J Mol Biol 2008; 384:673-89. [DOI: 10.1016/j.jmb.2008.09.064] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2008] [Revised: 09/21/2008] [Accepted: 09/23/2008] [Indexed: 12/01/2022]
|
154
|
Sun H, Stuckey JA, Zaneta NC, Qin D, Meagher JL, Qiu S, Lu J, Yang CY, Saito NG, Wang S. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem 2008; 51:7169-80. [PMID: 18954041 PMCID: PMC2688463 DOI: 10.1021/jm8006849] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Small molecules designed to mimic the binding of Smac protein to X-linked inhibitor of apoptosis protein (XIAP) are being pursued as a promising new class of anticancer drugs. Herein, we report the design, synthesis, and comprehensive structure-activity relationship studies of a series of conformationally constrained bicyclic Smac mimetics. Our studies led to the discovery of a number of highly potent and cell-permeable Smac mimetics and yielded important new insights into their structure-activity relationship for their binding to XIAP and for their activity in inhibition of cancer cell growth. Determination of the crystal structure of one potent Smac mimetic, compound 21, in complex with XIAP BIR3 provides the structural basis for its high-affinity binding to XIAP and for the design of highly potent Smac mimetics.
Collapse
Affiliation(s)
- Haiying Sun
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | - Jeanne A. Stuckey
- Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109, USA, Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA
| | - Nikolovska-Coleska Zaneta
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | - Dongguang Qin
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | | | - Su Qiu
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | - Jianfeng Lu
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | - Chao-Yie Yang
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
| | - Naoyuki G. Saito
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Shaomeng Wang
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA, Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA,To whom correspondence should be addressed. Phone: 734-615-0362. Fax: 734-647-9647. E-mail:
| |
Collapse
|
155
|
Rich RL, Myszka DG. Survey of the year 2007 commercial optical biosensor literature. J Mol Recognit 2008; 21:355-400. [DOI: 10.1002/jmr.928] [Citation(s) in RCA: 144] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
156
|
Sun H, Nikolovska-Coleska Z, Yang CY, Qian D, Lu J, Qiu S, Bai L, Peng Y, Cai Q, Wang S. Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res 2008; 41:1264-77. [PMID: 18937395 PMCID: PMC2676167 DOI: 10.1021/ar8000553] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Smac/DIABLO is a protein released from mitochondria into the cytosol in response to apoptotic stimuli. Smac promotes apoptosis at least in part through antagonizing inhibitor of apoptosis proteins (IAPs), including XIAP, cIAP-1, and cIAP-2. Smac interacts with these IAPs via its N-terminal AVPI binding motif. There has been an enormous interest in academic laboratories and pharmaceutical companies in the design of small-molecule Smac mimetics as potential anticancer agents. This task is particularly challenging because it involves targeting protein-protein interactions. Nevertheless, intense research has now generated potent, specific, cell-permeable small-molecule peptidomimetics and nonpeptidic mimetics. To date, two types of Smac mimetics have been reported, namely, monovalent and bivalent Smac mimetics. The monovalent compounds are designed to mimic the binding of a single AVPI binding motif to IAP proteins, whereas the bivalent compounds contain two AVPI binding motif mimetics tethered together through a linker. Studies from several groups have clearly demonstrated that both monovalent and bivalent Smac mimetics not only enhance the antitumor activity of other anticancer agents but also can induce apoptosis as single agents in a subset of human cancer cell lines in vitro and are capable of achieving tumor regression in animal models of human cancer. In general, bivalent Smac mimetics are 100-1000 times more potent than their corresponding monovalent Smac mimetics in induction of apoptosis in tumor cells. However, properly designed monovalent Smac mimetics can achieve oral bioavailability and may have major advantages over bivalent Smac mimetics as potential drug candidates. In-depth insights on the molecular mechanism of action of Smac mimetics have been provided by several independent studies. It was shown that Smac mimetics induce apoptosis in tumor cells by targeting cIAP-1/-2 for the rapid degradation of these proteins, which leads to activation of nuclear factor kappaB (NF-kappaB) and production and secretion of tumor necrosis factor alpha (TNFalpha). TNFalpha promotes formation of a receptor-interacting serine-threonine kinase 1 (RIPK1)-dependent caspase-8-activating complex, leading to activation of caspase-8 and -3/-7 and ultimately to apoptosis. For the most efficient apoptosis induction, Smac mimetics also need to remove the inhibition of XIAP to caspase-3/-7. Hence, Smac mimetics induce apoptosis in tumor cells by targeting not only cIAP-1/-2 but also XIAP. The employment of potent, cell-permeable, small-molecule Smac mimetics has yielded important insights into the regulation of apoptosis by IAP proteins. To date, at least one Smac mimetic has been advanced into clinical development. Several other Smac mimetics are in an advanced preclinical development stage and are expected to enter human clinical testing for the treatment of cancer in the near future.
Collapse
Affiliation(s)
- Haiying Sun
- Department of Internal Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
157
|
Nikolovska-Coleska Z, Meagher JL, Jiang S, Yang CY, Qiu S, Roller PP, Stuckey JA, Wang S. Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. Biochemistry 2008; 47:9811-24. [PMID: 18717598 PMCID: PMC2784912 DOI: 10.1021/bi800785y] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We have designed and synthesized a cyclic, bivalent Smac mimetic (compound 3) and characterized its interaction with the X-linked inhibitor of apoptosis protein (XIAP). Compound 3 binds to XIAP containing both BIR2 and BIR3 domains with a biphasic dose-response curve representing two binding sites with IC 50 values of 0.5 and 406 nM, respectively. Compound 3 binds to XIAPs containing the BIR3-only and BIR2-only domain with K i values of 4 nM and 4.4 microM, respectively. Gel filtration experiments using wild-type and mutated XIAPs showed that 3 forms a 1:2 stoichiometric complex with XIAP containing the BIR3-only domain. However, it forms a 1:1 stoichiometric complex with XIAP containing both BIR2 and BIR3 domains, and both BIR domains are involved in the binding. Compound 3 efficiently antagonizes inhibition of XIAP in a cell-free functional assay and is >200 times more potent than its corresponding monovalent compound 2. Determination of the crystal structure of 3 in complex with the XIAP BIR3 domain confirms that 3 induces homodimerization of the XIAP BIR3 domain and provides a structural basis for the cooperative binding of one molecule of compound 3 to two XIAP BIR3 molecules. On the basis of this crystal structure, a binding model of XIAP containing both BIR2 and BIR3 domains and 3 was constructed, which sheds light on the ability of 3 to relieve the inhibition of XIAP with not only caspase-9 but also caspase-3/-7. Compound 3 is cell-permeable, effectively activates caspases in whole cells, and potently inhibits cancer cell growth. Compound 3 is a useful biochemical and pharmacological tool for further elucidating the role of XIAP in regulation of apoptosis and represents a promising lead compound for the design of potent, cell-permeable Smac mimetics for cancer treatment.
Collapse
Affiliation(s)
- Zaneta Nikolovska-Coleska
- Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109
| | - Jennifer L. Meagher
- Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109
| | - Sheng Jiang
- Laboratory of Medicinal Chemistry, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland 21702
| | - Chao-Yie Yang
- Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109
| | - Su Qiu
- Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109
| | - Peter P. Roller
- Laboratory of Medicinal Chemistry, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland 21702
| | - Jeanne A. Stuckey
- Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, Biological Chemistry, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109
| | - Shaomeng Wang
- Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, To whom correspondence should be addressed. Phone: (734) 615-0362. Fax: (734) 647-9647.
| |
Collapse
|